Advances in Mycobacterial Isocitrate Lyase Targeting and Inhibitors

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F12%3A10127171" target="_blank" >RIV/00216208:11160/12:10127171 - isvavai.cz</a>

Result on the web

<a href="http://www.ingentaconnect.com/content/ben/cmc/2012/00000019/00000036/art00005" target="_blank" >http://www.ingentaconnect.com/content/ben/cmc/2012/00000019/00000036/art00005</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/092986712804485782" target="_blank" >10.2174/092986712804485782</a>

Result language

angličtina

Original language name

Advances in Mycobacterial Isocitrate Lyase Targeting and Inhibitors

Original language description

Isocitrate lyase plays a key role for survival of Mycobacterium tuberculosis in the latent form during a chronic stage of infection. This enzyme is important for M. tuberculosis during steady stage growth when it converts isocitrate to succinate and glyoxylate. Then, the glyoxylate is condensed with acetyl-CoA to form malate by malate synthase. The carbon conserving glyoxylate pathway has not been observed in mammals; therefore, it has been determined as a potential drug target for discovery of a new antituberculosis agent. Novel active molecules should shorten the duration of therapy, prevent resistance development and eliminate latent disease. The review summarizes recent progresses in isocitrate lyase inhibitors, overviews structural analogues of several metabolic intermediates (3-nitropropionate, 3-bromopyruvate, itaconate, itaconic anhydride), peptide inhibitors, and recently developed inhibitors with various chemical structures. The largest inhibitory activity against isocitrate

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FR - Pharmacology and apothecary chemistry

OECD FORD branch

—

Project

<a href="/en/project/NT13346" target="_blank" >NT13346: Design and enzyme targeting of antibacterial active compounds against multidrug resistant strains</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Current Medicinal Chemistry

ISSN

0929-8673

e-ISSN

—

Volume of the periodical

19

Issue of the periodical within the volume

36

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

12

Pages from-to

6126-6137

UT code for WoS article

000311959800005

EID of the result in the Scopus database

—